Personalized therapy for mycophenolate: consensus report by the international association of therapeutic drug monitoring and clinical toxicology
S Bergan, M Brunet, DA Hesselink… - Therapeutic drug …, 2021 - journals.lww.com
When mycophenolic acid (MPA) was originally marketed for immunosuppressive therapy,
fixed doses were recommended by the manufacturer. Awareness of the potential for a more …
fixed doses were recommended by the manufacturer. Awareness of the potential for a more …
Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients
This review aims to provide an extensive overview of the literature on the clinical
pharmacokinetics of mycophenolate in solid organ transplantation and a briefer summary of …
pharmacokinetics of mycophenolate in solid organ transplantation and a briefer summary of …
The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients
MR Costanzo, A Dipchand, R Starling… - The Journal of heart and …, 2010 - Elsevier
CHAIR: Costanzo MR: Midwest Heart Foundation, Lombard Illinois, USA TASK FORCE 1:
Dipchand A: Hospital for Sick Children, Toronto Ontario, Canada; Starling R: Cleveland …
Dipchand A: Hospital for Sick Children, Toronto Ontario, Canada; Starling R: Cleveland …
Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation
DRJ Kuypers, Y Le Meur, M Cantarovich… - Clinical journal of the …, 2010 - journals.lww.com
With the increasing use of mycophenolic acid (MPA) in solid organ transplantation, the need
for more accurate drug dosing has become evident. Personalized immunosuppressive …
for more accurate drug dosing has become evident. Personalized immunosuppressive …
Therapeutic drug monitoring of mycophenolate mofetil in transplantation
T Van Gelder, Y Le Meur, LM Shaw… - Therapeutic drug …, 2006 - journals.lww.com
A roundtable meeting to discuss the use of therapeutic drug monitoring (TDM) to guide
immunosuppression with mycophenolate mofetil was held in New York in December 2004 …
immunosuppression with mycophenolate mofetil was held in New York in December 2004 …
[HTML][HTML] Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies
LM Shaw, M Korecka, R Venkataramanan… - American Journal of …, 2003 - Elsevier
Mycophenolic acid (MPA), the active immunosuppressant form of the pro‐drug
mycophenolate mofetil (MMF), is a widely used component of immunosuppressive regimens …
mycophenolate mofetil (MMF), is a widely used component of immunosuppressive regimens …
Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion
LM Shaw, DW Holt, M Oellerich, B Meiser… - Therapeutic drug …, 2001 - journals.lww.com
BACKGROUND Pharmacokinetic monitoring of cyclosporine and tacrolimus, with the aim of
achieving adequate immunosuppression with minimized risk of graft rejection or toxicity, has …
achieving adequate immunosuppression with minimized risk of graft rejection or toxicity, has …
[HTML][HTML] Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation
D Cattaneo, N Perico, F Gaspari, E Gotti, G Remuzzi - Kidney international, 2002 - Elsevier
Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation.
Background Steroids have been shown to induce the hepatic glucuronyltransferase (GT) …
Background Steroids have been shown to induce the hepatic glucuronyltransferase (GT) …
The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation
RP Pelletier, B Akin, ML Henry… - Clinical …, 2003 - Wiley Online Library
Background: Mycophenolate mofetil (MMF) has proven to be a very effective drug for the
prevention of acute rejection following renal transplantation when dosed as prescribed at 2 …
prevention of acute rejection following renal transplantation when dosed as prescribed at 2 …
Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus
T Pawinski, M Hale, M Korecka… - Clinical …, 2002 - academic.oup.com
Background: Significant relationships between the mycophenolic acid (MPA) area under the
concentration–time curve (AUC0–12h) and the risks for acute rejection and side effects have …
concentration–time curve (AUC0–12h) and the risks for acute rejection and side effects have …